Broadwood Partners, L.P. Purchases 66,467 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical Company (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 66,467 shares of the stock in a transaction dated Wednesday, January 7th. The stock was bought at an average price of $22.00 per share, with a total value of $1,462,274.00. Following the purchase, the insider directly owned 15,422,904 shares in the company, valued at $339,303,888. This represents a 0.43% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, January 8th, Broadwood Partners, L.P. bought 3,240 shares of STAAR Surgical stock. The shares were bought at an average cost of $21.94 per share, for a total transaction of $71,085.60.
• On Tuesday, January 6th, Broadwood Partners, L.P. purchased 336,946 shares of STAAR Surgical stock. The stock was bought at an average cost of $21.62 per share, with a total value of $7,284,772.52.
• On Wednesday, November 19th, Broadwood Partners, L.P. acquired 309,132 shares of STAAR Surgical stock. The shares were bought at an average price of $26.42 per share, for a total transaction of $8,167,267.44.
• On Friday, November 21st, Broadwood Partners, L.P. acquired 797,486 shares of STAAR Surgical stock. The shares were bought at an average cost of $27.86 per share, for a total transaction of $22,217,959.96.
• On Thursday, November 20th, Broadwood Partners, L.P. bought 393,382 shares of STAAR Surgical stock. The stock was purchased at an average cost of $27.14 per share, with a total value of $10,676,387.48.

STAAR Surgical Stock Performance

STAA stock opened at $22.12 on Friday. The stock’s 50 day simple moving average is $25.01 and its 200 day simple moving average is $24.41. The company has a market cap of $1.10 billion, a P/E ratio of -11.34 and a beta of 1.00. STAAR Surgical Company has a fifty-two week low of $13.50 and a fifty-two week high of $30.81.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in STAA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in STAAR Surgical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock worth $518,000 after purchasing an additional 1,267 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of STAAR Surgical by 211,284.0% in the first quarter. Jones Financial Companies Lllp now owns 158,538 shares of the medical instruments supplier’s stock valued at $2,795,000 after acquiring an additional 158,463 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of STAAR Surgical by 33.4% during the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier’s stock valued at $9,606,000 after acquiring an additional 136,390 shares during the last quarter. Caxton Associates LLP purchased a new stake in shares of STAAR Surgical during the first quarter valued at approximately $1,051,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in STAAR Surgical by 11.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier’s stock worth $2,175,000 after acquiring an additional 12,841 shares during the period. 96.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of STAAR Surgical in a research note on Wednesday, October 8th. Piper Sandler reissued a “neutral” rating on shares of STAAR Surgical in a research report on Monday, October 27th. Canaccord Genuity Group upped their target price on shares of STAAR Surgical from $28.00 to $30.75 and gave the stock a “hold” rating in a report on Tuesday, December 9th. Finally, BTIG Research reiterated a “neutral” rating on shares of STAAR Surgical in a research note on Tuesday. Ten investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $23.42.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.